Vaxart, Inc. (NASDAQ:VXRT) Shares Purchased by Millennium Management LLC

Millennium Management LLC grew its stake in shares of Vaxart, Inc. (NASDAQ:VXRT) by 110.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,985,670 shares of the biotechnology company’s stock after purchasing an additional 2,095,274 shares during the quarter. Millennium Management LLC owned approximately 2.25% of Vaxart worth $2,660,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Vaxart by 19.9% during the first quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock valued at $10,984,000 after purchasing an additional 1,404,391 shares during the last quarter. Monaco Asset Management SAM bought a new position in shares of Vaxart during the second quarter valued at approximately $402,000. Kingswood Wealth Advisors LLC bought a new position in shares of Vaxart during the first quarter valued at approximately $32,000. Tidal Investments LLC bought a new position in Vaxart in the 1st quarter worth approximately $56,000. Finally, Sequoia Financial Advisors LLC bought a new position in Vaxart in the 2nd quarter worth approximately $65,000. 18.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer initiated coverage on Vaxart in a report on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price objective for the company.

Vaxart Price Performance

Shares of VXRT stock opened at $0.79 on Wednesday. Vaxart, Inc. has a 12-month low of $0.52 and a 12-month high of $1.54. The firm has a market capitalization of $139.01 million, a price-to-earnings ratio of -1.48 and a beta of 0.66. The business has a 50 day simple moving average of $0.83 and a 200 day simple moving average of $0.80.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The business had revenue of $6.40 million during the quarter, compared to the consensus estimate of $65.70 million. During the same period last year, the company earned ($0.16) earnings per share. On average, equities analysts anticipate that Vaxart, Inc. will post -0.47 EPS for the current fiscal year.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.